The diagnostic value of Hsp90α in monitoring treatment responses in lung cancer

Background/aim: Heat shock protein 90α (Hsp90α) is considered a tumor biomarker in many human malignancies. This study investigated the diagnostic value of Hsp90α combined with other traditional lung cancer biomarkers (CEA, CYFRA21-1, and NSE) and its role in monitoring the treatment response of lung cancer patients. Materials and methods: A total of 205 patients with lung cancer and 186 patients with lung benign disease who were admitted to our hospital were enrolled from 2018 to 2020. The 205 patients included 76 cases of squamous, 92 cases of adenocarcinoma, and 37 cases of small cell lung cancer. There were 49 patients with TNM I+II and 156 patients with TNM III+IV. A total of 10 mL baseline peripheral venous blood samples and subsequent peripheral venous blood samples (7 days after two cycles of chemotherapy) were collected, and the levels of Hsp90α, carcinoembryonic antigen (CEA), Cytokeratin 19 fragments (CYFRA21-1), and neuron-specific enolase (NSE) were detected by ELISA kit. Results: Hsp90α was obviously higher in serum from patients with lung cancer than in patients with benign lung disease (p < 0.0001). Moreover, Hsp90α levels were higher in patients with advanced-stage (stage III-IV) lung cancer compared to those with early-stage (stage I-II). Hsp90α level was significantly decreased following treatment with chemotherapy in the progress partial response group (p = 0.017), whereas the level of Hsp90α was significantly higher after chemotherapy treatment in the progressive disease group (p < 0.0001). In addition, compared with CYFRA21-1, CEA, or NSE alone, the AUC of Hsp90α combined with CYFRA21-1, CEA, or NSE were significantly higher in the diagnosis of adenocarcinoma or small-cell lung cancer. Conclusion: Hsp90α combined with CYFRA21-1, CEA, and NSE can be used as diagnostic indicators of lung cancer. The Hsp90α level can be used to monitor treatment response.

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018; 68 (6): 394- 424. doi: 10.3322/caac.21492
2. Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. Respiratory Medicine 2012; 106 (4): 473-492. doi: 10.1016/j.rmed.2011.10.016
3. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colon carcinoma by immunological tolerance and absorption techniques. Journal of Experimental Medicine 1965; 121 (3): 439-462. doi: 10.1084/jem.121.3.439
4. Chiu NF, Yang HT. High-sensitivity detection of the lung cancer biomarker CYFRA21-1 in serum samples using a CarboxylMoS(2) functional film for SPR-based immunosensors. Frontiers in Bioengineering and Biotechnology 2020; 8: 234. doi: 10.3389/fbioe.2020.00234
5. Genet S, Visser E, van den Borne B, Soud MY, Belderbos HNA et al. Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer. Oncotarget 2020; 11 (27): 2660-2668. doi: 10.18632/ oncotarget.27664
6. Wong DS, Jay DG. Emerging roles of extracellular Hsp90 in cancer. Advances in Cancer Research 2016; 129: 141-163. doi: 10.1016/bs.acr.2016.01.001
7. Li J, Buchner J. Structure, function and regulation of the hsp90 machinery. Biomedical Journal 2013; 36 (3): 106-117. doi: 10.4103/2319-4170.113230
8. Schwartz H, Scroggins B, Zuehlke A, Kijima T, Beebe K et al. Combined HSP90 and kinase inhibitor therapy: insights from the cancer genome atlas. Cell Stress & Chaperones 2015; 20 (5): 729-741. doi: 10.1007/s12192-015-0604-1
9. Abdel-Rahman O. Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer. Clinical & Translational Oncology 2018; 20 (4): 550-556. doi: 10.1007/s12094-017-1739-6
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009; 45 (2): 228-247. doi: 10.1016/j.ejca.2008.10.026
11. Jayaprakash P, Dong H, Zou M, Bhatia A, O’Brien K et al. Hsp90α and Hsp90β together operate a hypoxia and nutrient paucity stress-response mechanism during wound healing. Journal of Cell Science 2015; 128 (8): 1475-1480. doi: 10.1242/ jcs.166363
12. Devarakonda CV, Kita D, Phoenix KN, Claffey KP. Patientderived heavy chain antibody targets cell surface HSP90 on breast tumors. BMC Cancer 2015; 15: 614. doi: 10.1186/ s12885-015-1608-z
13. Hance MW, Dole K, Gopal U, Bohonowych JE, JezierskaDrutel A et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. Journal of Biological Chemistry 2012; 287 (45): 37732-37744. doi: 10.1074/jbc.M112.389015
14. Nagaraju GP, Long TE, Park W, Landry JC, TaliaferroSmith L et al. Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. Molecular Carcinogenesis 2015; 54 (10): 1147-1158. doi: 10.1002/mc.22185
15. Shi Y, Liu X, Lou J, Han X, Zhang L et al. Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses. Clinical Cancer Ressearch 2014; 20 (23): 6016-6022. doi: 10.1158/1078-0432.CCR-14-0174
16. Jiang ZF, Wang M, Xu JL. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Science 2018; 194: 1-6. doi: 10.1016/j. lfs.2017.12.020
17. Záčková M, Moučková D, Lopotová T, Ondráčková Z, Klamová H, Moravcová J. Hsp90 - a potential prognostic marker in CML. Blood Cells Molecules and Disease 2013; 50 (3): 184- 189. doi: 10.1016/j.bcmd.2012.11.002